# Incyte Shares ESMO 2026 Data for Pancreatic, Colorectal, Ovarian Cancers

> Incyte's ESMO 2026 data shows promise for pancreatic, colorectal, and ovarian cancer treatments.
- Title: Incyte Shares ESMO 2026 Data for Pancreatic, Colorectal…
- Summary: Incyte's ESMO 2026 data shows promise for pancreatic, colorectal, and ovarian cancer treatments. Incyte presents ESMO 2026 data indicating potential benefits…
- Keywords: incyte, esmo, pancreatic cancer, colorectal cancer, ovarian cancer, esmo 2026, money, business, Shares, 2026, Data, Pancreatic
- Source: Seekingalpha — https://seekingalpha.com/article/4955613-incyte-digesting-the-esmo-updates-in-pancreatic-colorectal-and-ovarian-cancer
- Author: Biotech Beast
- Published: 2026-10-20T18:40:36+00:00
- Read time: 1 min
- Topics: incyte, esmo, pancreatic cancer, colorectal cancer, ovarian cancer, esmo 2026, money, business
## Incyte ESMO 2026 Data
Incyte Corporation presents promising ESMO 2026 data for three solid tumor pipeline assets, aiming to offset Jakafi's looming loss of exclusivity.
## KRAS G12D Inhibitor 734
KRAS G12D inhibitor '734 shows competitive efficacy in pancreatic and colorectal cancer, with notable 37% response rate when used in combination in pre-treated colorectal cancer patients.
## INCA33890 and CDK2 Inhibitor
INCA33890 confirms differentiated activity in colorectal cancer with liver metastasis, but phase 3 outcomes remain difficult to predict.
## Key takeaway

Incyte presents ESMO 2026 data indicating potential benefits for three cancer treatments.